Incredible stuff 🔥 "the recent approval of resmetirom will open the floodgates for quantitative MRI biomarkers of the liver. The radiology community must prepare for this new era. This is our challenge & our opportunity. We must rise to the occasion." pubs.rsna.org/doi/10.1148/ra…

Over the next five days, I will highlight Mayo leaders who exemplify our five leadership competencies with the hope their stories will inspire others to come forward to lead healthcare transformation at this critical juncture. Read the first article here: bit.ly/3ZFPK3P

Excited to have our abstract/poster accepted for the #MASHTAG25 meeting this year in Park City! #livertwitter Some highlights: 🟢 US Installations: MRE 1,300; VCTE 1,600 🟢Utilization: MRE +20% in 2022; VCTE +3% 🟢Cost (Medicate rates): MRE $206-$289; VCTE $232-$324 "MRE and

Thank you to all the imaging centers and radiology practices working tirelessly to empower patients and clinicians with greater confidence in diagnosing and managing liver disease. #MASLD #MASH🙏

Interesting paper here. Couple of quick thoughts: - a bad test (low sensitivity) is the worst thing. Patients value most: "if I have the disease, I want the test to find it early" - False Positives: the data here seem odd. As the FP% decreases from 40% to 20% and then 10%, the

Funding from the NIH contributed to the development of 354 out of 356 (99.4%) of the new drugs approved by the FDA between 2010 and 2019, and 🚨 100% 🚨 of FDA approved drugs btw 2010-2016. NIH funding is the backbone of American biomedical innovation. #protecttheNIH

Who does MASLD guru Rohit Loomba think should go on resmetirom? GUILD Conference

Happy to be co-author on a great and highly practical study (lead author Yasaman Vali) from the LITMUS Consortium on the clinical factors that might require adjusted thresholds to noninvasive tests (NITs) for liver fibrosis assessment. Some key takeaways: 🟢 NITs like FIB-4,

Funny moment this morning watching my kids get ready for school, and then mom comes on TV talking about tariffs/trade 🙂

Liver health made simple! We're crafting memorable slogans to help clinicians and patients easily identify when MRE liver stiffness readings of 3-5 kPa indicate Rezdiffra treatment. "MRE 3 to 5? Rezdiffra keeps your liver alive!" "3 to 5 on MRE? Rezdiffra is the key." "MRE

"In clinical guidelines, we'll advocate for MRI-PDFF for MASH assessment and VCTE for fibrosis assessment." "Sir, why not do MRE simultaneously with PDFF, since it only takes a minute longer, is more accurate, and actually makes the exam cheaper?" "Nobody knows." #livertwitter

.Mayo Clinic's breakthrough innovations need partners like you. License our technologies and join us in shaping the future of medicine. businessdevelopment.mayoclinic.org/technology-lic… #innovation #collaboration

Evaluating Diagnostic Accuracy and Cost Implications in MASLD Fibrosis Staging resoundant.com/single-post/ev…

A new study in Nature caught my attention for its innovative approach to a long-standing challenge: noninvasively assessing liver inflammation in MASH. lnkd.in/evmimxGB The team (Vanderbilt Radiology; Xiaoyu Jiang, John Gore et al) introduces MR cytometry - an imaging

We need to spread the word about MASH Awareness is low, particularly amongst people at risk and frontline providers Hot of the presses in Hepatology Communications journals.lww.com/hepcomm/fullte… #easl2025

19% Most imaging biomarkers try to prove they’re specific. MRE did the opposite early on - RSNA QIBA experts were working to standardize MRE for *clinical use* first - not just for clinical trials. So the widely cited 19% repeatability coefficient (RC) for MRE wasn’t

Cardiovascular risk estimates miss the mark in people with MASH Heart disease is the most important risk for patients with MASH but the commonly used risk equations just don’t work New paper in AJG - The American Journal of Gastroenterology

🚨🚨 Did you catch it? Lilly hinted on their last earnings call that their Phase 3 MASLD trial for tirzepatide and retatrutide may be biopsy-free—using only non-invasive tests like MRE and MRI-PDFF. This could be a watershed moment for metabolic liver disease trials: faster,

MASLD has become the most common chronic liver disease worldwide. Giovanni Targher, MD, Luca Valenti, MD (Luca Valenti), and Christopher D. Byrne, MB, ChB, review the features of the disease as well as pharmacotherapies targeting the associated liver and